Merck’s $208m acquisition of Abceutics aims to enhance ADC safety

TORL BioTherapeutics secures $158 million to advance its ADC oncology pipeline through Series B-2 financing

BioCity’s first-in-class ADC targeting Glypican 3 clears FDA’s IND application

Genmab to acquire ADC maker ProfoundBio